Literature DB >> 15795244

Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys.

Michael S Seaman1, Sampa Santra, Michael H Newberg, Valerie Philippon, Kelledy Manson, Ling Xu, Rebecca S Gelman, Dennis Panicali, John R Mascola, Gary J Nabel, Norman L Letvin.   

Abstract

The expression of particular major histocompatibility complex (MHC) class I alleles can influence the rate of disease progression following lentiviral infections. This effect is a presumed consequence of potent cytotoxic T-lymphocyte (CTL) responses that are restricted by these MHC class I molecules. The present studies have examined the impact of the MHC class I allele Mamu-A*01 on simian/human immunodeficiency virus 89.6P (SHIV-89.6P) infection in unvaccinated and vaccinated rhesus monkeys by exploring the contribution of dominant-epitope specific CTL in this setting. Expression of Mamu-A*01 in immunologically naive monkeys was not associated with improved control of viral replication, CD4+ T-lymphocyte loss, or survival. In contrast, Mamu-A*01+ monkeys that had received heterologous prime/boost immunizations prior to challenge maintained higher CD4+ T-lymphocyte levels and better control of SHIV-89.6P replication than Mamu-A*01- monkeys. This protection was associated with the evolution of high-frequency anamnestic CTL responses specific for a dominant Mamu-A*01-restricted Gag epitope following infection. These data indicate that specific MHC class I alleles can confer protection in the setting of a pathogenic SHIV infection by their ability to elicit memory CTL following vaccination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795244      PMCID: PMC1069575          DOI: 10.1128/JVI.79.8.4580-4588.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other.

Authors:  P J Goulder; Y Tang; S I Pelton; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

3.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

4.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

5.  Immune control of HIV-1 after early treatment of acute infection.

Authors:  E S Rosenberg; M Altfeld; S H Poon; M N Phillips; B M Wilkes; R L Eldridge; G K Robbins; R T D'Aquila; P J Goulder; B D Walker
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

6.  Control of SIV rebound through structured treatment interruptions during early infection.

Authors:  F Lori; M G Lewis; J Xu; G Varga; D E Zinn; C Crabbs; W Wagner; J Greenhouse; P Silvera; J Yalley-Ogunro; C Tinelli; J Lisziewicz
Journal:  Science       Date:  2000-11-24       Impact factor: 47.728

7.  Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.

Authors:  J D Lifson; J L Rossio; R Arnaout; L Li; T L Parks; D K Schneider; R F Kiser; V J Coalter; G Walsh; R J Imming; B Fisher; B M Flynn; N Bischofberger; M Piatak; V M Hirsch; M A Nowak; D Wodarz
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.

Authors:  T Matano; M Kano; H Nakamura; A Takeda; Y Nagai
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

9.  Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.

Authors:  D H Barouch; S Santra; M J Kuroda; J E Schmitz; R Plishka; A Buckler-White; A E Gaitan; R Zin; J H Nam; L S Wyatt; M A Lifton; C E Nickerson; B Moss; D C Montefiori; V M Hirsch; N L Letvin
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

10.  Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.

Authors:  Michael S Seaman; Ling Xu; Kristin Beaudry; Kristi L Martin; Margaret H Beddall; Ayako Miura; Anna Sambor; Bimal K Chakrabarti; Yue Huang; Robert Bailer; Richard A Koup; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

View more
  12 in total

1.  Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

Authors:  Nia Tatsis; Julie C Fitzgerald; Arturo Reyes-Sandoval; Kimberly C Harris-McCoy; Scott E Hensley; Dongming Zhou; Shih-Wen Lin; Ang Bian; Zhi Quan Xiang; Amaya Iparraguirre; Cesar Lopez-Camacho; E John Wherry; Hildegund C J Ertl
Journal:  Blood       Date:  2007-05-17       Impact factor: 22.113

2.  Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Authors:  Zane Kraft; Katharine Strouss; William F Sutton; Brad Cleveland; For Yue Tso; Patricia Polacino; Julie Overbaugh; Shiu-Lok Hu; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

3.  CD8+ and CD20+ lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype.

Authors:  Hanwen Mao; Bernard A P Lafont; Tatsuhiko Igarashi; Yoshiaki Nishimura; Charlie Brown; Vanessa Hirsch; Alicia Buckler-White; Reza Sadjadpour; Malcolm A Martin
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys.

Authors:  Norman L Letvin; John R Mascola; Yue Sun; Darci A Gorgone; Adam P Buzby; Ling Xu; Zhi-Yong Yang; Bimal Chakrabarti; Srinivas S Rao; Jörn E Schmitz; David C Montefiori; Brianne R Barker; Fred L Bookstein; Gary J Nabel
Journal:  Science       Date:  2006-06-09       Impact factor: 47.728

5.  Vaccination reduces simian-human immunodeficiency virus sequence reversion through enhanced viral control.

Authors:  Edwin R Manuel; Wendy W Yeh; Harikrishnan Balachandran; Ryon H Clarke; Michelle A Lifton; Norman L Letvin
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

6.  Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.

Authors:  Aurelio Cafaro; Stefania Bellino; Fausto Titti; Maria Teresa Maggiorella; Leonardo Sernicola; Roger W Wiseman; David Venzon; Julie A Karl; David O'Connor; Paolo Monini; Marjorie Robert-Guroff; Barbara Ensoli
Journal:  J Virol       Date:  2010-06-16       Impact factor: 5.103

7.  Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.

Authors:  Lisa E Hensley; Sabue Mulangu; Clement Asiedu; Joshua Johnson; Anna N Honko; Daphne Stanley; Giulia Fabozzi; Stuart T Nichol; Thomas G Ksiazek; Pierre E Rollin; Victoria Wahl-Jensen; Michael Bailey; Peter B Jahrling; Mario Roederer; Richard A Koup; Nancy J Sullivan
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

8.  Mamu-A01/K(b) transgenic and MHC Class I knockout mice as a tool for HIV vaccine development.

Authors:  Jinliang Li; Tumul Srivastava; Ravindra Rawal; Edwin Manuel; Donna Isbell; Walter Tsark; Corinna La Rosa; Zhongde Wang; Zhongqi Li; Peter A Barry; Katharine D Hagen; Jeffrey Longmate; Don J Diamond
Journal:  Virology       Date:  2009-02-27       Impact factor: 3.616

9.  HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1.

Authors:  Marcus Altfeld; Elizabeth T Kalife; Ying Qi; Hendrik Streeck; Mathias Lichterfeld; Mary N Johnston; Nicole Burgett; Martha E Swartz; Amy Yang; Galit Alter; Xu G Yu; Angela Meier; Juergen K Rockstroh; Todd M Allen; Heiko Jessen; Eric S Rosenberg; Mary Carrington; Bruce D Walker
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

Review 10.  HIV DNA Vaccine: Stepwise Improvements Make a Difference.

Authors:  Barbara K Felber; Antonio Valentin; Margherita Rosati; Cristina Bergamaschi; George N Pavlakis
Journal:  Vaccines (Basel)       Date:  2014-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.